中国China Patent OfficeCNIPAPatent LawprosecutionUpdates and Changes
2024年1月25日

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 1: Delayed Examination

December 2023 appears to have been an exceptionally busy and fruitful month in the China patent space. Following the State Council’s approval of the long-awaited Patent Law Implementation Regulations (“Regulations”, similar to the CFR in the US) in November, the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new Patent Examination Guidelines (“Guidelines”, equivalent to the MPEP in the US), along with specific implementation dates and transitional methods. We will, over the coming period, undertake a detailed analysis and commentary on these amendments and their consequential impacts. Today’s article will focus on the delayed examination.

Delayed Patent Examination

Under normal Chinese prosecution procedures, applicants must request substantive examination by a three-year deadline in order to begin the substantive examination process.

In 2019, CNIPA amended the Patent Examination Guidelines to formally introduce the Delayed Examination procedure. The procedure allows applicants to file requests for delayed examination for invention and design patent applications. The Guidelines also provide that, if necessary, the Patent Office may initiate examination on its own and notify the applicant that the period of “delayed examination” is terminated.

Summary of the Changes

The latest amended Regulations and Guidelines in 2023 have made some updates to the delayed patent examination procedure, which are summarized below. The main changes include the possibility of withdrawing the delay request, the addition of a 1-year delayed examination option for Utility Model patents, and counting the delayed examination period for Design patents by months instead of by years.

  Before the 2023 change After the 2023 change
Invention patent Can request a delay of 1, 2, or 3 years

(at the time of filing the request for substantive examination)

No change
Utility Model patent No Can request a delay of 1 year (at the time of filing)
Design patent Can request a delay of 1, 2, or 3 years

(at the time of filing)

Can request a delay of up to 36 months, counting by months (at the time of filing)
Can it be withdrawn? No Yes, and then will be examined in normal order
Is patent compensation (PTA) available? Not Applicable No

Using Delayed Examination in Patent Strategy

Having more flexibility over when to start examination has many potential strategic advantages.

For example, applicants can take a “wait and see” approach, delaying examination in China to see (and possibly use) examination results from corresponding applications in other jurisdictions. Using delayed examination in conjunction with other tools (e.g., PPH), could reduce overall patent prosecution costs in a large portfolio.

Applicants can also make use of delayed examination to postpone the timing of certain public disclosures to better align with business objectives. This could be especially useful in the cases of Utility models and design patents, which typically grant (and therefore publish) quite quickly.

There are other benefits to delayed examination. For instance, an inventor may need extra time to generate more experimental data to submit to the patent office to demonstrate surprising technical effect. Similarly, a business may need more time to determine which claims in the patent application are most important to the company.

Finally, keeping a parent application pending by delaying examination offers various strategic advantages, such as preserving the ability to file voluntary divisional applications, deterring competitors, and more precisely aligning overall patent strategy with product development timelines.

In the latest commentary on China’s Ministry of Justice website, Professor Cui Guobin summarizes it well. “This revision strengthens the advantages of delayed examination, allowing applicants to draft appropriate claims based on the latest technological progress, market competition conditions, or changes in the international standards, thereby making patent protection more targeted. They can also take advantage of the latest patent examination policies, such as supplementary experimental data, storage media in the computer field, protection of software products, etc.”[1]

Limitations of Delayed Examination

However, there are limitations of the delayed examination system. It’s important to note that delayed examination merely postpones the examination process and does not provide additional time for applicants to amend their applications (i.e., the voluntary amendment window stays the same). Additionally, it offers no assurance of a specific timeline for receiving examination results after the delay. Importantly, the actual duration of the delay becomes an "applicant-induced unreasonable delay." As a consequence, this period is counted against the applicant when calculating patent term compensation (“PTA”), a topic we will delve into in a separate article.

Conclusion

Overall, delayed examination is a helpful tool that patent practitioners can use to map out creative patent strategies. Combined with other tools such as the Patent Prosecution Highway (PPH), priority examination, divisional applications, voluntary amendments, and more, applicants have access to many interesting options and pathways to meet their overall IP and business goals. The recent changes broaden the availability of these tools and also adds flexibility to the system overall.

If you would like to have more information on this matter or would like to have our advice, please feel free to contact us at [email protected].

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

  1. Cui, Guobin, Intellectual Property Law Research Center, Tsinghua University Law School, “Commentary on the latest revisions to the Implementing Rules of the Patent Law”, Official Website of the Ministry of Justice, People’s Republic of China. December 21, 2023 https://www.moj.gov.cn/pub/sfbgw/zcjd/202312/t20231221_492072.html

About the Authors

Yolanda Wang is a Principal, Chinese Patent Attorney, and Chinese Patent Litigator at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

Jennifer Che, J.D. is Managing Director and a US Patent Attorney at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

其他文章

First Ever Successful Invalidation Challenge Due to Unauthorized Foreign Filing

2023年3月8日
What does an invention “completed” in China mean? China and the US are similar in that both countries highly value national security, and thus have rules regulating the exportation of technology and information from within their borders. This includes new inventions that arise from within their respective borders. As such, both governments require inventors who […]

A Detailed Dive into China’s New Patent Term Extension Provisions

2020年12月11日
This article is a part of a larger article that highlights the newest draft implementation rules of the new Chinese Patent Law. This particular article takes a detailed dive into the patent term extension/adjustment provisions. One of the biggest and most exciting provisions in the newly amended patent law is patent term extension for delay […]

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

2025年2月4日
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]

我们的过去活动

Top crossarrow-right